Q2 FY2026 · ended Jun 30, 2026 · Revenue $2.98M, -17.5% YoY · Filed Aug 13, 2026
CV Sciences, Inc. (CVSI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $3.0 million and a net loss of $775,000. Free cash flow was $13,000. As of Jun 30, 2026 it held $266,000 in cash and investments and $236,000 in total debt.
Revenue
$2.98M
-17.5% vs year-ago quarter
Net income
$-775,000
-196.9% vs year-ago quarter
Operating cash flow
$20,000
-93.0% vs year-ago quarter
Free cash flow
$13,000
-94.5% vs year-ago quarter
EPS
$0.00
Dividend per share
None
Shares outstanding
225.83M
+22.6% vs year-ago quarter
Net cash
$30,000
Q2 FY2026
Operating margin
-7.6%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CVSI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1510964
- Former names
- CannaVEST Corp. (until Jan 4, 2016); Foreclosure Solutions, Inc. (until Nov 30, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $3.2M | $3.3M | $3.3M | $3.6M |
| Operating income | -$301,000 | -$318,000 | -$75,000 | -$275,000 | -$131,000 |
| Net income | -$775,000 | -$643,000 | -$206,000 | -$382,000 | -$261,000 |
| Diluted EPS | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Operating cash flow | $20,000 | $101,000 | -$354,000 | -$259,000 | $287,000 |
| Free cash flow | $13,000 | $98,000 | -$363,000 | -$270,000 | $238,000 |
| Total assets | $6.5M | $6.7M | $7.0M | $7.0M | $8.0M |
| Total liabilities | $5.0M | $5.2M | $5.5M | $5.5M | $6.1M |
| Stockholders' equity | $1.6M | $1.5M | $1.5M | $1.5M | $1.8M |
| Cash and investments | $266,000 | $309,000 | $278,000 | $381,000 | $886,000 |
| Total debt | $236,000 | $355,000 | $2.0M | $1.7M | $2.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 23, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 13, 2026 | May 14, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Mar 27, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 14, 2026 | May 14, 2026 |
All 431 CV Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.